Takeda's GI revenue up 24.8% in Q3 — 5 insights

Takeda reported net revenues of $881.4 billion yen ($7.71 billion) in its third quarter fiscal year 2017 results.

Here's what you should know:

1. Takeda increased revenues 3.6 percent year-over-year.

2. Takeda's gastroenterology division was its second strongest, with revenue increasing 24.8 percent year-over-year. Entyvio and Takecab led the growth.

3. Takeda's U.S.-based revenue increased 16.7 percent year-over-year.

4. Takeda's CEO Christophe Weber said in a release, "Our growth drivers continued to deliver robust double-digit revenue growth, which together with our cost management initiatives led to a significant margin expansion. … Although we expect headwinds in the second half of the year, we are still confident to raise our outlook for the full year as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."

5. Concerning end-of-year outlooks, Takeda expects earnings of $1.720 trillion yen ($15.07 billion).

More articles on gastroenterology: 
GI leader to know: Dr. Christie Choi of Texas Digestive Disease Consultants
8 GI centers to know for October
Stock market week-in-review for 5 large GI companies — Oct. 23-27

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months